Everything below concerns anti-doping analysis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-23. Numbers and descriptions here follow the published literature rather than marketing material.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
On 31 October 1899, General Sir Redvers Henry Buller, a much-respected commander, arrived in South Africa with the Army Corps, made up of the 1st, 2nd and 3rd divisions. Buller originally intended an offensive straight up the railway leading from Cape Town through Bloemfontein to Pretoria. Finding on arrival that British troops were under siege, he split his army corps into detachments to relieve the besieged garrisons. One division, led by Lieutenant General Lord Methuen, was to follow the Western Railway to the north and relieve Kimberley and Mafeking. A smaller force of 3,000, led by Major General William Gatacre, was to push north towards the railway junction at Stormberg and secure the Cape Midlands District from Boer raids and rebellions by Boer inhabitants. Buller led the major part of the army corps to relieve Ladysmith to the east. The initial results of this offensive were mixed, with Methuen winning bloody skirmishes in the Battle of Belmont on 23 November, the Battle of Graspan on 25 November, and at a larger engagement, the Battle of Modder River, on 28 November resulting in British losses of 71 dead and over 400 wounded. British commanders had been trained on the lessons of the Crimean War and were adept at battalion and regimental set pieces, with columns manoeuvring in jungles, deserts and mountainous regions. What British generals failed to comprehend was the impact of destructive fire from trench positions and the mobility of cavalry raids.
== Y == Ada Yonath (1939–2026). Israeli crystallographer at the Weizmann Institute of Science, best known for her pioneering work on the structure of the ribosome. Nobel Prize in Chemistry (2009). Member Natl. Acad. Sci. USA. Frank Young FRS (1908–1988). British biochemist at Cambridge University, where he was Sir William Dunn Professor for many years. William John Young (1878–1942). British biochemist at the University of Melbourne who worked on fermenting enzymes in yeast extract, and discovered “Harden–Young ester” (fructose 1,6-bisphosphate).
=== Age === Age estimation attempts to determine the skeletal/biological age-at-death. The primary assumption is that an individual's skeletal age is closely associated with their chronological age. Age estimation can be based on patterns of growth and development or degenerative changes in the skeleton. A variety of skeletal series methods to assess these types of changes have been developed. For instance, in children age is typically estimated by assessing dental development, ossification and fusion of specific skeletal elements, or long bone length. For children, different teeth erupt from the gums serially are the most reliable for telling a child's age. However, fully developed teeth are less indicative. In adults, degenerative changes to the pubic symphysis, the auricular surface of the ilium, the sternal end of the 4th rib, and dental attrition are commonly used to estimate skeletal age. Until the age of about 30, human bones keep growing. Different bones fuse at different points of growth. This development can vary across individuals. Wear and tear on bones further complicates age estimates. Often, estimates are limited to 'young' (20–35 years), 'middle' (35–50 years), or 'old' (50+ years).
government agreed to spend $1.2 billion to purchase 1.7 million doses of Molnupiravir, a Merck product, if it were to be approved by regulators to treat COVID-19. In October 2021, the company said that the drug reduces the risk of hospitalization or death by around 50% for patients with mild or moderate cases of COVID-19 and that it would seek Emergency Use Authorization for the drug. In July 2021, Robert M. Davis became CEO, succeeding Kenneth Frazier, who became executive chairman. In July 2021, Merck completed the corporate spin-off of Organon & Co. In September 2021, Merck announced it would acquire Acceleron Pharma for $11.5 billion, gaining control over Sotatercept, used in the treatment of pulmonary hypertension, and luspatercept-aamt. In September 2022, the company announced it would acquire Vence, a livestock management company for an undisclosed sum, incorporating it within Merck Animal Health. In December 2022, the company announced a licensing deal with Kelun-Biotech of China whereby it would expand its early cancer pipeline with a set of antibody-drug conjugates; this follows an earlier agreement between the two companies to co-develop such drugs. In April 2023, Merck announced it would acquire Prometheus Biosciences Inc for $10.8 billion. In December 2023, Merck announced it had partnered with Owkin to develop artificial intelligence-powered digital pathology diagnostics that could be used to identify patients suitable for immunotherapies.
Sources: en.wikipedia.org
=== Austrian Empire and Austria-Hungary === In 1814, by decisions of the Congress of Vienna, Tyrol was reunified and returned to Austria, becoming a crown land (Kronland) of the Austrian Empire. The formerly Salzburgian Zillertal, Brixental and Matrei were also permanently integrated into Tyrol. Administratively Vorarlberg was attached to the reconstituted Tyrol (formally as "the princely county of Tyrol with Vorarlberg" – die gefürstete Grafschaft Tirol mit Vorarlberg) as Kreis Bregenz until it became a crown land in its own right in the 1861 February Patent. Tyrol-proper (i.e. excluding Vorarlberg) was until 1849 divided into six Kreise: Oberinnthal (or Imst), Unterinnthal (Schwaz), Pusterthal (Bruneck), Etsch (Bozen), Trient and Rovereto. In 1849 this was reduced to three: Innsbruck, Brixen and Trient, which broadly corresponded with the modern North Tyrol, South + East Tyrol and Trentino respectively. These Kreise were briefly divided into modern-style political districts but were recentralised and divided into smaller "office districts" from 1853. Following the Austro-Hungarian Compromise of 1867 Tyrol was a Cisleithanian (Austrian) crown land within Austria-Hungary. The Kreise and office districts were abolished and political districts re-introduced in 1868.
== Misconceptions == Drosophila is often referred to as a pest due to its tendency to live in human settlements where fermenting fruit is found. Flies may collect in homes, restaurants, stores, and other locations. The name and behavior of this species of fly have led to the misconception in Australia and elsewhere that it is a biological security risk. While other "fruit fly" species do pose a risk, D. melanogaster is simply attracted to fruit that is already rotting; it does not cause the fruit to rot.
Errors in biosynthetic pathways can have deleterious consequences including the malformation of macromolecules or the underproduction of functional molecules. Below are examples that illustrate the disruptions that occur due to these inefficiencies.
== Further reading == Gustavo V. Barbosa-Canovas, Liliana Alamilla-Beltran, Efren Parada-Arias, Jorge Welti-Chanes (2015) Water Stress in Biological, Chemical, Pharmaceutical and Food Systems. New York, NY : Springer New York : Imprint: Springer. ISBN 978-1-4939-2578-0 Jamuna Aswathanarayn & Rai, V. Ravishankar (2015). Microbial Food Safety and Preservation Techniques. Boca Raton : CRC Press Taylor & Francis Group. ISBN 9781138033801
Packaged breakfast cereals were considerably more convenient than a product that had to be cooked, and as a result of this convenience (and marketing that emphasized the point), they became popular. Battle Creek, Michigan, was a center both of the Seventh-day Adventist Church and of innovation in the ready-to-eat cereal industry, and indeed, the church had a substantial impact on the development of cereal goods through the person of John Harvey Kellogg (1851–1943). Son of an Adventist factory owner in Battle Creek, Kellogg was encouraged by his church to train in medicine at Bellevue Hospital Medical College in New York City in 1875. After graduating, he became medical superintendent at the Western Health Reform Institute in Battle Creek, established in 1866 by the Adventists to offer their natural remedies for illness. Many wealthy industrialists came to Kellogg's sanitarium for recuperation and rejuvenation. In Battle Creek sanitarium guests found fresh air, exercise, rest, hydrotherapy, a strict vegetarian diet, and abstinence from alcohol, tobacco, coffee, and tea. (They were accustomed to breakfasts of ham, eggs, sausages, fried potatoes, hot biscuits, hotcakes (pancakes), and coffee.) To supplement the center's vegetarian regimen, Kellogg experimented with granola. Soon afterwards he began to experiment with wheat, resulting in a lighter, flakier product. In 1891 he acquired a patent and then in 1895 he launched the Cornflakes brand, which overnight captured a national market. Soon there were forty rival manufacturers in the Battle Creek area. His brother William K.
Sources: en.wikipedia.org
=== Dislike of elderly === As a trainee nurse Norris often refused to work with elderly patients, saying he "didn't want to be working with that type of person". He admitted to police he found elderly patients challenging. Police would later discover that Norris had repeatedly mistreated elderly patients in the early months of his nursing career at the same Leeds hospitals in which he would later go on to murder patients. In one instance, an elderly man asked Norris to empty his catheter bag, only for Norris to flatly refuse and insist he do it himself, before going off duty. The elderly man then collapsed after trying to reach the bathroom by himself. Other patients stated that Norris had treated them in an offhand and callous manner, and that Norris had an apparent dislike of old people. Two elderly ex-patients said that Norris had verbally abused them after they rang an emergency buzzer on a ward when an elderly patient climbed out of bed, with Norris then saying to them "I hope you suffer" and "rot in hell".
=== Development suspended === EQ-101 (BNZ132) – intravenous – alopecia areata – interleukin 15 receptor antagonist, interleukin 2 receptor antagonist, interleukin 9 receptor antagonist Research programme: SNA based alopecia therapeutics - Exicure/AbbVie – alopecia – gene expression modulators XCUR-17 – topical – alopecia – RNA interference
Nuclear emulsions are similar to photographic emulsions, except that they are used in particle physics to detect high-energy elementary particles. Whilst an emulsion roughly corresponds to a mixture of at least two immiscible liquids mixed together, by contrast emulsification is the process of dispersing two or more immiscible liquids together through the use of an emulsifier (e.g., lecithin in a mixture of oil and water). Nanoemulsification is the process of emulsification in the nanoscale. A nanoemulsion is a particular kind of emulsion, with droplet sizes on the order of 100 nm.
==== Effectors ==== Pseudomonas syringae isolates carry a range of virulence factors called type III secretion system (T3SS) effector proteins. These proteins primarily function to cause disease symptoms and manipulate the host's immune response to facilitate infection. The major family of T3SS effectors in P. syringae is the hrp gene cluster, coding for the Hrp secretion apparatus.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.